[{"indications": "Indications\u00a0treatment of acute migraine", "name": "ALMOTRIPTAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.4 Antimigraine drugs", "4.7.4.1 Treatment of acute migraine", "5HT1-receptor agonists", "ALMOTRIPTAN"], "cautions": "Cautions\u00a0see under 5HT1-receptor agonists above; sensitivity to sulfonamides; interactions: Appendix 1 (5HT1 agonists)", "side-effects": "Side-effects\u00a0see under 5HT1-receptor\r\nagonists above; also transient increase in blood pressure,\r\ndrowsiness; less commonly diarrhoea, dyspepsia, dry\r\nmouth, chest pain, palpitation, paraesthesia, headache, myalgia, bone\r\npain, tinnitus; very rarely myocardial infarction,\r\nand tachycardia; seizures also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106090.htm", "doses": ["12.5\u00a0mg as soon as possible after onset repeated after\r\n2 hours if migraine recurs (patient not responding should not take\r\nsecond dose for same attack); max. 25\u00a0mg in 24 hours; child and adolescent under 18 years not recommended"], "pregnancy": "Pregnancy\u00a0\n(From 5HT1-receptor agonists: British National Formulary)\nPregnancy\u00a0There is limited experience of using 5HT1-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk."}]